Thermo Fisher Scientific Inc.

Company facts

Industry

Measuring & Controlling Devices, NEC

Headquarters

Waltham, Massachusetts

Most recent report

10-Q, filed Jul 31, 2026

Incorporated

Delaware

Filings on record

1,006+ filings

On EDGAR

CIK 97745

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 2 of 11 sections worth reading, with 0 positive, 5 notable, and 0 negative flags.

• Financial Statements (Item 1)

  Primary financials with Clario acquisition, divestiture, debt raise, restructuring.
  Notable

  • Remaining performance obligations $29.70B, about 52% expected within 12 months.
  • Clario acquisition on 3/24/2026 for $9.1B: cash paid $5.8B, debt settled $3.2B, contingent $108M.
  • Agreed to sell microbiology business for ~$1.075B (cash + seller note), expected close Q3 2026.

• Management's Discussion (Item 2)

  MD&A with detailed segment results, liquidity, and acquisition impacts – essential for understanding Q2 2026 performance.
  Notable

  • Clario acquisition (March 24, 2026) drove $441M Q2 growth in clinical research business.
  • Acquisitions used $8.87B cash in H1, primarily the Clario deal.

What changed: Jun 2026 vs. Mar 2026

About 10% of TMO's Jun 2026 10-Q is new information. 29 paragraphs were added, 86 changed, and 17 removed. Below are the most important lines SECSift identified.

• Item 2 31
• Item 1 24
• Item 5 2
• Item 4 1
• Item 6 1